Table 1.
Patient demographics
| VKA (n = 389) | NOAC (n = 376) | p-value | ||
|---|---|---|---|---|
| Age, mean ± SD | 70.6 ± 8.8 | 70.3 ± 9.1 | 0.68 | |
| Male, n (%) | 209 (70.4%) | 235 (64.6%) | 0.13 | |
| Type of NOAC | NA | |||
| Apixaban, n (%) | NA | 58 (15.4%) | ||
| Dabigatran, n (%) | NA | 24 (6.4%) | ||
| Rivaroxaban, n (%) | NA | 291 (77.4%) | ||
| Edoxaban, n (%) | NA | 3 (0.8%) | ||
| Previous thrombosis, n (%) | 34 (8.7%) | 12 (3.2%) | 0.001 | |
| Previous embolism, n (%) | 19 (4.9%) | 5 (1.3%) | 0.006 | |
| CAD, n (%) | 42 (10.8%) | 34 (9%) | 0.47 | |
| Previous stroke/TIA, n (%) | 29 (7.5%) | 26 (6.9%) | 0.78 | |
| Additional medical therapy | ||||
| ASA, n (%) | 10 (2.6%) | 3 (0.8%) | 0.09 | |
| P2Y12 inhibitor, n (%) | 5 (1.3%) | 21 (5.6%) | 0.001 | |
| Antidiabetic drugs, n (%) | 63 (16.2%) | 37 (9.8%) | 0.01 | |
| Antidepressants, n (%) | 10 (2.6%) | 15 (4%) | 0.31 | |
| Polypharmacy (>3), n (%) | 208 (53.5%) | 172 (45.7%) | 0.04 | |
VKA vitamin‑K antagonist, NOAC non-vitamin‑K oral anticoagulant, CAD coronary artery disease, TIA transient ischaemic attack, ASA acetylsalicylic acid